These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
655 related items for PubMed ID: 27293206
1. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Prasad V, Tiling N, Denecke T, Brenner W, Plöckinger U. Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206 [Abstract] [Full Text] [Related]
2. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D. J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855 [Abstract] [Full Text] [Related]
3. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A. J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147 [Abstract] [Full Text] [Related]
12. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions. Cingarlini S, Ortolani S, Salgarello M, Butturini G, Malpaga A, Malfatti V, DʼOnofrio M, Davì MV, Vallerio P, Ruzzenente A, Capelli P, Citton E, Grego E, Trentin C, De Robertis R, Scarpa A, Bassi C, Tortora G. Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872 [Abstract] [Full Text] [Related]
13. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients. Cleary JO, Yeung J, McMeekin H, Wilhelm T, Wagner T. Nucl Med Commun; 2016 Nov; 37(11):1197-205. PubMed ID: 27399848 [Abstract] [Full Text] [Related]
14. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B. J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222 [Abstract] [Full Text] [Related]
15. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A. Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886 [Abstract] [Full Text] [Related]
18. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. Mapelli P, Partelli S, Salgarello M, Doraku J, Pasetto S, Rancoita PMV, Muffatti F, Bettinardi V, Presotto L, Andreasi V, Gianolli L, Picchio M, Falconi M. Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478 [Abstract] [Full Text] [Related]
19. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. Sadowski SM, Weisbrod AB, Ellis R, Patel D, Alimchandani M, Quezado M, Millo C, Venzon DJ, Nilubol N, Linehan WM, Kebebew E. J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849 [Abstract] [Full Text] [Related]